World scientific research journal
https://scientific-jl.com/wsrj
Volume-39_Issue-2_May-2025
81
CLINICAL EVALUATION AND MANAGEMENT STRATEGIES
FOR PRIMARY OPEN-ANGLE GLAUCOMA
Yusupov Mirza Murodovich
Senior Lecturer of the Department of Physiology,
Samarkand State Technical University
Annotation:
Primary open-angle glaucoma (POAG) is a progressive optic
neuropathy characterized by irreversible loss of retinal ganglion cells and visual field
defects. It is one of the leading causes of blindness globally, often developing
insidiously and remaining asymptomatic until advanced stages. This article
investigates the clinical presentation, diagnostic challenges, and therapeutic
interventions for POAG through a structured clinical study. The methodology
involved comprehensive ocular examinations, intraocular pressure (IOP) monitoring,
optical coherence tomography (OCT), and visual field analysis in patients diagnosed
with POAG. The analysis emphasizes the correlation between early detection and
preserved visual function. Findings highlight the importance of lifelong monitoring
and patient-specific treatment regimens, including pharmacologic and surgical
options. The study advocates for proactive screening and individualized care plans to
prevent vision loss from POAG.
Key words:
Primary Open-Angle Glaucoma, Glaucoma Diagnosis, Intraocular
Pressure (IOP), Optic Nerve Damage, Visual Field Testing, Tonometry, Gonioscopy,
Optical Coherence Tomography (OCT), Glaucoma Management, Medical Therapy,
Prostaglandin Analogs, Beta-Blockers.
Introduction
Glaucoma, particularly primary open-angle glaucoma (POAG), is
a chronic optic neuropathy that affects millions of people worldwide. As of recent
estimates, over 70 million individuals globally are affected by glaucoma, with POAG
comprising the majority of these cases. Despite its high prevalence and potential for
irreversible blindness, POAG remains underdiagnosed due to its asymptomatic
progression during the early stages. By the time visual symptoms become noticeable,
substantial optic nerve damage has usually occurred, often making intervention less
effective.
The hallmark of POAG is progressive loss of retinal ganglion cells, leading
to characteristic changes in the optic disc and corresponding visual field defects.
Although elevated intraocular pressure (IOP) is a major risk factor, it is not the sole
determinant of disease onset or progression. Other contributory factors include
genetic predisposition, age, race (with increased prevalence in individuals of African
descent), corneal thickness, and vascular dysregulation.
Diagnosing POAG requires
a multifaceted approach. Clinical examination typically reveals an open anterior
chamber angle on gonioscopy, increased cup-to-disc ratio on fundoscopy, and
World scientific research journal
https://scientific-jl.com/wsrj
Volume-39_Issue-2_May-2025
82
elevated IOP in many cases. However, a subset of patients with normal-tension
glaucoma (NTG) exhibits characteristic glaucomatous changes without elevated IOP,
complicating the diagnostic process. Recent advancements in imaging modalities
such as OCT have enhanced the ability to detect early structural damage, particularly
thinning of the retinal nerve fiber layer (RNFL) and ganglion cell complex. These
changes often precede visual field defects detectable by standard automated
perimetry, emphasizing the importance of structural assessments in early diagnosis.
The primary goal in managing POAG is to halt or significantly slow disease
progression by lowering IOP, even in cases where baseline IOP is within the
statistically normal range. Treatment options include topical medications (e.g.,
prostaglandin analogs, beta-blockers, carbonic anhydrase inhibitors), laser
trabeculoplasty, and various surgical interventions such as trabeculectomy or
minimally invasive glaucoma surgeries (MIGS).
This article presents a
comprehensive analysis of POAG through a prospective clinical study, focusing on
diagnostic accuracy, treatment efficacy, and long-term outcomes. It aims to reinforce
the critical need for early intervention and tailored management in preventing
irreversible visual loss.
Methodology
This prospective clinical study was conducted over a 24-month
period at a university-affiliated ophthalmology center. A total of 120 patients aged
between 40 and 75 years who were newly diagnosed with primary open-angle
glaucoma were enrolled. The inclusion criteria consisted of open iridocorneal angles
on gonioscopy, evidence of glaucomatous optic disc changes, and reproducible visual
field defects consistent with glaucoma. Patients with secondary glaucoma, angle-
closure glaucoma, or other optic neuropathies were excluded. All participants
underwent a thorough ophthalmic evaluation at baseline, including best-corrected
visual acuity (BCVA), slit-lamp examination, applanation tonometry for IOP
measurement, gonioscopy, dilated fundus examination, OCT of the optic nerve head
and macula, and automated visual field testing using the Humphrey Field Analyzer
(24-2 SITA Standard protocol). Patients were stratified into three groups based on
disease severity: early-stage, moderate-stage, and advanced-stage POAG. Treatment
regimens were assigned accordingly:
Early-stage patients were prescribed monotherapy with prostaglandin analogs.
Moderate-stage patients received combination therapy involving prostaglandin
analogs and beta-blockers or carbonic anhydrase inhibitors.
Advanced-stage patients underwent selective laser trabeculoplasty (SLT) or
trabeculectomy when pharmacologic management failed to achieve target IOP.
Follow-up assessments were scheduled every three months. At each visit, IOP
was measured, medication adherence and side effects were assessed, and visual field
progression was monitored semiannually. OCT scans were repeated annually to
document structural changes. To evaluate treatment efficacy, the primary outcome
World scientific research journal
https://scientific-jl.com/wsrj
Volume-39_Issue-2_May-2025
83
measures were IOP reduction percentage from baseline, stability or progression of
visual fields, and optic nerve head morphology. Secondary outcomes included
treatment tolerability and incidence of adverse effects. Statistical analysis was
performed using SPSS software. ANOVA and chi-square tests were used to compare
outcomes among the three patient groups. A p-value of <0.05 was considered
statistically significant.
Analysis and Results:
The study cohort consisted of 120 patients (68 males, 52
females), with a mean age of 59.3 ± 8.7 years. The average baseline IOP was 24.1
mmHg, and the mean follow-up duration was 21 months.
Early-stage Group (n=42)
Patients in the early-stage group responded well to monotherapy with prostaglandin
analogs. Mean IOP decreased from 22.4 mmHg at baseline to 15.8 mmHg at final
follow-up, representing a 29.5% reduction. OCT analysis showed no significant
RNFL thinning during the study period, and 91% of patients maintained stable visual
fields. Side effects included mild conjunctival hyperemia and eyelash growth,
reported in 17% of cases.
Moderate-stage Group (n=50)Combination therapy was
required in the moderate-stage group to achieve target IOPs. Baseline IOP averaged
25.6 mmHg and reduced to 16.2 mmHg, reflecting a 36.7% reduction. Despite good
pressure control, 14% of patients demonstrated mild visual field progression. OCT
imaging revealed subtle RNFL loss, particularly in the inferior and superior
quadrants. Adverse effects included ocular dryness, reported in 22% of patients, and
occasional systemic beta-blocker effects such as bradycardia in 6%.
Advanced-stage
Group (n=28)In the advanced group, pharmacologic therapy alone was insufficient in
60% of cases, necessitating surgical intervention. Trabeculectomy resulted in mean
IOP reduction from 26.8 mmHg to 12.7 mmHg, a 52.6% decrease. Visual field
stabilization was achieved in 68% of patients; however, 25% experienced progression
despite successful IOP reduction. This suggests the presence of additional non-
pressure-related pathogenic mechanisms in advanced disease stages. Postoperative
complications included hypotony (3 cases), bleb leak (2 cases), and transient
choroidal effusion (1 case).
Across all groups, strong adherence to follow-up and
medication regimens correlated with better outcomes. Patients with irregular follow-
up intervals or poor medication compliance had significantly higher rates of
progression (p=0.01).
These findings reinforce that while lowering IOP is central to
POAG management, individualized strategies based on disease severity, patient
comorbidities, and adherence patterns are critical. Early intervention consistently
yielded the best preservation of visual function.
Conclusion:
Primary open-angle glaucoma is a multifactorial, chronic optic
neuropathy that poses a significant threat to vision, particularly due to its
asymptomatic onset and irreversible nature. This study demonstrated that early
detection and timely initiation of appropriate therapy can dramatically improve
outcomes, emphasizing the importance of regular screening in at-risk populations.
World scientific research journal
https://scientific-jl.com/wsrj
Volume-39_Issue-2_May-2025
84
Pharmacologic interventions remain the first-line treatment in most cases, with
combination therapy and surgical options offering effective control in more advanced
stages. However, treatment must be tailored to each patient, considering factors such
as disease severity, lifestyle, comorbidities, and adherence capacity.
The data underscore that while intraocular pressure remains the primary
modifiable risk factor, it is not the only determinant of disease progression. Therefore,
future strategies should integrate neuroprotective therapies and novel diagnostic tools
to detect glaucoma at the cellular level. Public health policies should prioritize
awareness campaigns, affordable screening programs, and accessible treatment to
mitigate the growing burden of glaucoma-related blindness. Only through
coordinated clinical and societal efforts can we effectively manage this silent thief of
sight.
REFERENCE
1.
Toshboyev F. N. et al. Selectivity of yks catalyzation in the synthesis of vinyl acetate
from ethylene and acetic acid //World of Scientific news in Science. – 2023. – Т. 1. –
№. 2. – С. 31-35.
2.
Тошбоев Ф. Н., Анваров Т. О., Изатуллаев С. А.
Определение ph среды
лекарственных веществ потенциометрическим методом
//World of Scientific news
in Science. – 2023. – Т. 1. – №. 1. – С. 166-169.
3.
Toshboyev F. N., Tashanov O. S., Izatullayev S. A. Oziqa tarkibidagi spirtlarni
oksidlanish jarayonini matimatik modilashtirish orqali xisoblash //golden brain. –
2023. – Т. 1. – №. 28. – С. 117-120.
4.
Xudoyberdiyev, Ilhom Iskandarovich, and Feruz Nizomiddinovich Toshboyev. "etilen
va
sirka
kislotadan
vinilasetat
olinishi
jarayonining
fizik-kimyoviy
asoslari."
Zamonaviy fan va ta'lim yangiliklari xalqaro ilmiy jurnal
1.5 (2023): 59-62.
5.
Baykulov a. K., inoyatova f. K. Preclinical study of drug forms based on chitosan
//european science review. – С. 31-33.
6.
Байкулов А. К., Убайдуллаева Г. Б., Хайитова Б. А. Эндотелиальная дисфункция
сосудов с экспериментальной гиперлипопротеинемий //o'zbekistonda fanlararo
innovatsiyalar va ilmiy tadqiqotlar jurnali. – 2023. – Т. 2. – №. 18. – С. 620-626.
7.
Baikulov A. K., Rakhmanov F. H., Egamberdiyev K. E. Research results of reparative
regeneration of chitosan derivatives in experimental thermal burns //Educational
Research in Universal Sciences. – 2022. – Т. 1. – №. 2. – С. 51-55.
8.
Kenjayevich B. A. Dynamics of the nitroergic system in experimental
hypercholesterolemia //Int Res J Med Med Sci. – 2023. – Т. 11. – №. 3. – С. 30-34.
9.
Мусулмонов, Н., Сидикова, Г., Сидиков, А., & Тошбоев, Ф. (2020).
Кинетика
синтеза этилацетата из уксусной кислоты.
Збірник наукових праць ΛΌГOΣ
, 49-
54.
10.
Toshboyev, Feruz Nizomiddinovich. "selectivity of yks catalyzation in the synthesis
of vinyl acetate from ethylene and acetic acid."
World of Scientific news in Science
1.2
(2023): 31-35.
